Article
Author(s):
A study from Merck has demonstrated high response to grazoprevir/elbasvir with and without ribavirin across various hepatitis C virus populations, including difficult-to-cure patients.
A study from Merck has demonstrated high response to grazoprevir/elbasvir with and without ribavirin (RBV) across various hepatitis C virus (HCV) populations, including difficult-to-cure patients.
The phase 2 clinical trial examined the efficacy of the investigational drug in treatment-naïve cirrhotic patients and those who failed to respond to previously treatment with peg-interferon/ribavirin (PR) for chronic HCV genotype 1 (GT1) infection.
For the treatment-naïve cirrhotic patients and PR null-responders, the rates of sustained viral response (SVR) at 12 weeks ranged from 90% to 100%. The PR-null patients taking RBV for 18 weeks saw the most success.
Among HCV mono-infected and HIV/HCV co-infected patients, the treatment was slightly less effective, as those individuals achieved 87% to 98% SVR at 12 weeks, according to the press release.
Some patients experienced fatigue (23%), headache (20%), nausea (15%), and diarrhea (10%), the release stated.
“Merck is committed to developing an efficacious, well-tolerated therapy suitable for a broad spectrum of patients with HCV,” said Eliav Barr, MD, vice president of infectious diseases at Merck Research Laboratories, in a press release. “We are encouraged by the findings for grazoprevir/elbasvir in the C-WORTHy trial and look forward to advancing our broad phase 3 program, which includes hard-to-cure patients that are of the highest need and least studied to date.”
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.